Table 1 Comparing molecular and clinical indicators between EGFRvIII(−) (n = 56) and EGFRvIII(+) (n = 15) GBM patients.

From: EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis

Characteristics

EGFR vIII(−)

EGFRvIII(+)

P value

n

56

15

 

Age (mean (SD))

49.59 (14.61)

55.67 (14.35)

0.155

TMB(mean (SD))

7.75 (21.76)

2.38 (1.98)

0.466

Gender (%)

  

0.634

 Male

36 (64.3%)

8 (53.3%)

 

 Female

20 (35.7%)

7 (46.7%)

 

WHO grade(%)

  

0.044*

 1

1 (1.8%)

0 (0.0%)

 

 2

15 (26.8%)

1 (6.7%)

 

 3

10 (17.9%)

0 (0.0%)

 

 4

30 (53.6%)

14 (93.3%)

 

Tumor Type (%)

  

0.015*

 Astrocytoma, IDH-mutant

17 (31.5%)

0 (0.0%)

 

 Diffuse midline glioma, H3 K27-altered

1 (1.9%)

2 (13.3%)

 

 Glioblastoma, IDH-wildtype

24(44.4%)

12 (80.0%)

 

 Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted

8 (14.8%)

0 (0.0%)

 

 Pilocytic astrocytoma

2 (3.7%)

1 (6.7%)

 

 Pleomorphic xanthoastrocytoma

2 (3.7%)

0 (0.0%)

 

PRS type(%)

  

0.175

 Primary

45 (80.4%)

15 (100.0%)

 

 Progress

1 (1.8%)

0 (0%)

 

 Recurrent

10 (17.9%)

0 (0%)

 

IDH mutation status (%)

  

0.003**

 Mutant

26 (46.4%)

0 (0.0%)

 

 Wildtype

30 (53.6)

15 (100.0%)

 

1p19q codeletion status(%)

  

0.231

 Codel

9 (16.1%)

0 (0.0%)

 

 Non-codel

45 (80.4%)

14 (93.3%)

 

 NA

2 (3.6%)

1 (6.7%)

 

MGMTp methylation status(%)

  

0.412

 methylated

26 (46.4%)

4 (26.7%)

 

 un-methylated

28 (50.0%)

9 (60.0%)

 

 NA

2 (3.6%)

2 (13.3%)

 

EGFR amplification (%)

  

<0.001***

 Yes

4 (7.1%)

8 (53.3%)

 

 No

48 (85.7%)

4 (26.7%)

 

 NA

4 (7.1%)

3 (20%)

 

EGFR mutation (%)

  

0.918

 no_mutation

46 (82.1%)

9 (60.0%)

 

 missense_mutation

6 (10.7%)

2 (13.3%)

 

 NA

4 (7.1%)

4 (26.7%)

 

TERT promoter mutation (%)

  

0.328

 Yes

26 (46.4%)

10 (66.7%)

 

 No

28 (50.0%)

5 (33.3%)

 

 NA

2 (3.6%)

0 (0.0%)

 

+7/−10 copy number changes (%)

  

0.364

 Yes

3 (5.4%)

4 (26.7%)

 

 No

11 (19.6%)

4 (26.7%)

 

 NA

42 (75.0%)

7 (46.7%)

 

H3_K27M mutation (%)

  

0.115

 Yes

1 (1.8%)

2 (13.3%)

 

 No

33 (58.9%)

5 (33.3%)

 

 NA

22 (39.3%)

8 (53.3%)

 

CDKN2A/B homozygous deletion (%)

  

0.821

 Yes

5 (8.9%)

4 (26.7%)

 

 No

11 (19.6%)

5 (33.3%)

 

 NA

40 (71.4%)

6 (40.0%)

 

TP53 mutation (%)

  

0.107

 Yes

24 (42.9%)

2 (13.3%)

 

 No

30 (53.6%)

11(73.3%)

 

 NA

2 (3.6%)

2(13.3%)

 

ATRX mutation (%)

  

0.114

 Yes

13 (23.2%)

0 (0.0%)

 

 No

41 (73.2%)

13 (86.7%)

 

 NA

2 (3.6%)

2 (13.3%)

 

BRAF_V600E mutation (%)

  

1.000

 Yes

2 (3.6%)

0 (0.0%)

 

 No

54 (96.4%)

15 (100.0%)

 
  1. T tests and chi-square tests or Fisher’s exact tests were used to compare continuous variables and categorical variables. T-tests were used to analyze differences between two independent groups, and one-way analysis of variance (ANOVA) and least significant difference (LSD) tests were used to analyze differences between more than two groups.
  2. SD standard deviation, TMB tumor mutational burden, PRS primary-recurRENt subtype, IDH isocitrate dehydrogenase, MGMTp O6-methylguanine-DNA methyltransferase promoter, TERT telomerase reverse tranase, BRAF V-raf murine sarcoma viral oncogene homolog B1, V600E the most common missense mutation of BRAF, NA not available.
  3. *, **, and ***indicate P < 0.05, P < 0.01, and P < 0.001, respectively.
  4. The bolded values signify that their corresponding variables have achieved statistical significance(P < 0.05).
Back to article page